Drug name
Last update: Oct 2026VH-079 (VH4527079) (mAb)
Developer(s)
Drug information
Not provided
VH4527079; VH079
Not applicable (investigational; no brand name assigned)
Biotherapeutic
mAb (Monoclonal antibody) — Human monoclonal antibody for HIV
Active / In Development (Phase 1/2/3)
VH4527079 (VH-079) is an investigational human bispecific broadly neutralizing antibody (bNAb) in development by ViiV Healthcare for the treatment and prevention of HIV-1. It is in first-in-human evaluation under NCT06652958, a phase 1 open-label study of single subcutaneous or intravenous dosing in healthy adults, and multiple intravenous dosing in healthy adults and in people with HIV. It might be a bispecific antibody with an anticipated target of every-6-month dosing interval by subcutaneous or intravenous administration. The targeted epitopes are not yet disclosed, nor the half-life extension strategy.
Not approved in any jurisdiction as of September 2026. Investigational; phase 1 (first-in-human), active and not recruiting.
No marketing authorisation application identified. Developed under a US FDA IND held by ViiV Healthcare.
Therapeutic area(s)
- HIV
- Treatment
Administration route
Subcutaneous, Intravenous
Associated long-acting platforms
Monoclonal antibodies and antibody drug conjugates
Use of drug
- Administered by a nurse
- To be determined
- Every 6 months
Dosage
to be determined
to be determined
to be determined
Not provided
Not provided
Related entries
Not provided
Additional information
Developer(s)
ViiV Healthcare
ViiV Healthcare is a pharmaceutical company that specializes in the development of therapies for HIV infection. The company is headquartered in Brentford in the United Kingdom and was initially formed in November 2009 as a part of a joint venture between GlaxoSmithKline and Pfizer. Shionogi joined in October 2012
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL